Capricor治疗师HOPE-2研究显示,Deramiocel提高了DMD病人的心脏功能和运动技能,具有有利的安全特征。 Capricor Therapeutics' HOPE-2 study shows deramiocel improves cardiac function and motor skills in DMD patients with a favorable safety profile.
Capricor Therapeutics 报告了其关于 deramiocel（一种治疗杜氏肌营养不良症 （DMD） 的 HOPE-2 研究的三年积极结果。 Capricor Therapeutics reported positive three-year results from its HOPE-2 study on deramiocel, a treatment for Duchenne muscular dystrophy (DMD). 调查结果显示,病人的心脏功能和运动技能有了显著提高,具有有利于长期使用的安全特征。 The findings showed significant improvements in cardiac function and motor skills in patients, with a favorable safety profile for long-term use. 在世界肌肉协会大会上分享了这些结果,导致Capricor的Nasdaq股票价格上涨9.31%。 These results were shared at the World Muscle Society Congress, leading to a 9.31% increase in Capricor's stock price on Nasdaq.